BHST

BioHarvest Sciences Inc. Common Stock

$1.79

2.29%
SectorConsumer DefensiveIndustryPackaged FoodsCountryCanada

BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules.

Source: Yahoo Finance
AI summary

Price & performance

1M+12.2%
3M-22.4%
YTD-68.1%
1Y-83.0%
52-week range—
Beta0.57
Full chart and returns against a benchmark

Q-Score

39/ 100

Quality against peers; 50 is the peer median.

Growth49
Risk42
Performance39
Valuation37
Profitability37
Leverage64
Sentiment49
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$34.5M+37.0%
Net income-$11.1M
Net margin-32.3%+19.0 pts
Historical fundamentals

Revenue exposure

Regions, segments, customers and suppliers

Valuation

BHSTIndustryP/E—53.49P/S1.180.75EV/EBITDA—16.50P/B1.591.61PEG—5.24
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report, before the open
EPS estimate$-0.14
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate